Moleac's Flagship Product NeuroAiD Named Asia Pacific Neurological Disorders New Product Innovation of the Year At the Frost & Sullivan Best Practices Awards

Absolutely nothing in here shows any proof this actually works except for the marketing. Check out the bolded in pink  statement below.
Moleac's Flagship Product NeuroAiD Named Asia Pacific Neurological Disorders New Product Innovation of the Year At the Frost & Sullivan Best Practices Awards

SINGAPORE, Oct. 13, 2016 /PRNewswire/ -- NeuroAiD^TM has been named New Product Innovation of the Year by Frost & Sullivan. This award recognizes healthcare products that are bringing innovative solutions for neurological disorders by pushing the boundaries of the usual practices. This award also acknowledges Moleac for its effort and continuous investment in NeuroAiD^TM's Research and Development. Mr. David Picard, CEO of Moleac, received the 2016 Frost & Sullivan Asia Pacific New Product Innovation Award at the awards ceremony held this evening at Conrad Singapore. The ceremony was attended by leaders from the healthcare sector.

Frost & Sullivan followed a rigorous measurement-based methodology to select NeuroAiD^TM as the recipient. Its independent panel of judges included senior members across various offices at Frost & Sullivan. The judging panel looked at market performance indicators, including revenue growth, market share, availabilities, geographical expansion and marketing strategies.

Dr. M. Shaillender, Industry Analyst, Healthcare Practice - Asia Pacific at Frost & Sullivan, said, "Stroke rehabilitation is an underserved segment in the pharmaceutical industry. Moleac aims to address the existing gaps in stroke therapy with an unconventional approach similar to 'reverse innovation.' NeuroAiD^TM is a product originating from Traditional Chinese Medicine that has demonstrated excellent attributes in post-stroke recovery, however, without any scientific and clinical evidence. Moleac's team was instrumental in identifying and decoding the underlying neuromodulatory properties to translate it into a therapeutic drug supported by clinical evidence for neurological disorders."

He further adds, "As one of the first therapies of its kind, NeuroAiD^TM is today accepted as an innovative treatment for post-stroke recovery. It is approved and marketed in over 35 countries as a supplement for stroke rehabilitation. Executing well in its vision, Moleac is on a trajectory to expand the horizons of NeuroAiD^TM into a mainstream therapeutic drug for neurological disorders."

David Picard, CEO of Moleac, said, "I am delighted to receive this award from Frost & Sullivan while we are celebrating the 10 years' anniversary of NeuroAiD^TM. Having launched NeuroAiD^TM in 2006, we have been focusing our efforts on making NeuroAiD^TM available to stroke sufferers around the world. NeuroAiD^TM is the first medicine to support stroke recovery, and this is a huge unserved need for millions of suffers. In 2016, over 20,000 patients benefited from NeuroAiD^TM worldwide and we aim at making NeuroAiD^TM available to more patients in the coming years."

He continued to add, "I would like to thank all those who have contributed to NeuroAiD^TM's development over the past 10 years. This includes our academic partners, who have shown interest in our approach enabling its clinical development, our investors who have trusted us, and of course my colleagues who have made this venture a success. Without their support, NeuroAiD^TM would not be where it is today. We keep investing in Research with several on-going clinical studies to provide first-class evidences of NeuroAiD^TM's benefits in other unserved neurological disorders."

NeuroAiD^TM is a natural medicine originating from Traditional Chinese Medicine. In addition to its excellent safety profile, clinical trials have shown that patients taking NeuroAiD^TM for 3 months have higher chances to reach functional recovery, with prolonged benefits over the long-term as published in Cerebrovascular Diseases (April 2015). About 3,000 subjects have been included in clinical trials and Moleac is currently supporting additional international clinical trials to demonstrate the potential of NeuroAiD^TM in other neurological disorders.

About Moleac: Moleac is a Singapore-based biopharmaceutical company that dedicates itself to finding and developing new medicines for the unmet needs of patients worldwide.

About NeuroAiD^TM: NeuroAiD^TM is a post-stroke recovery treatment to help stroke survivors achieve a faster and better recovery. Moleac also markets NeuroAiD II, a simplified formula. Both products are shown to be equivalent in pharmacology. It currently reaches out to patients in over 35 countries.

Contact details:

Global Marketing
Moleac Pte Ltd
+65 6211 3710
marketing@moleac.com

SOURCE Moleac Pte Ltd

What Is the Evidence for Physical Therapy Poststroke? A Systematic Review and Meta-Analysis

Will this now lead to therapists actually knowing what therapies are evidence-based?
A review of stroke rehabilitation and physiotherapy from 1990
So it took 24 years to come to a conclusion! Wow, Just wow!
In 1994, these therapists had no Theoretical basis of stroke rehab
So I'm not convinced that this will do anything unless we get a great stroke association to deliver this information to all therapists. And I really don't consider this very good evidence since I doubt there was any objective measurement of dead/damaged neurons. Thus making any repeatability impossible.

What Is the Evidence for Physical Therapy Poststroke? A Systematic Review and Meta-Analysis

Janne Marieke Veerbeek,¹ Erwin van Wegen,¹ Roland van Peppen,² Philip Jan van der Wees,³ Erik Hendriks,⁴ Marc Rietberg,¹ and Gert Kwakkel^1,5,*

Terence J. Quinn, Editor

Author information ► Article notes ► Copyright and License information ►

Go to:

Abstract

Background

Physical therapy (PT) is one of the key disciplines in interdisciplinary stroke rehabilitation. The aim of this systematic review was to provide an update of the evidence for stroke rehabilitation interventions in the domain of PT.

Methods and Findings

Randomized controlled trials (RCTs) regarding PT in stroke rehabilitation were retrieved through a systematic search. Outcomes were classified according to the ICF. RCTs with a low risk of bias were quantitatively analyzed. Differences between phases poststroke were explored in subgroup analyses. A best evidence synthesis was performed for neurological treatment approaches. The search yielded 467 RCTs (N=25373; median PEDro score 6 [IQR 5–7]), identifying 53 interventions. No adverse events were reported. Strong evidence was found for significant positive effects of 13 interventions related to gait, 11 interventions related to arm-hand activities, 1 intervention for ADL, and 3 interventions for physical fitness. Summary Effect Sizes (SESs) ranged from 0.17 (95%CI 0.03–0.70; I²=0%) for therapeutic positioning of the paretic arm to 2.47 (95%CI 0.84–4.11; I²=77%) for training of sitting balance. There is strong evidence that a higher dose of practice is better, with SESs ranging from 0.21 (95%CI 0.02–0.39; I²=6%) for motor function of the paretic arm to 0.61 (95%CI 0.41–0.82; I²=41%) for muscle strength of the paretic leg. Subgroup analyses yielded significant differences with respect to timing poststroke for 10 interventions. Neurological treatment approaches to training of body functions and activities showed equal or unfavorable effects when compared to other training interventions. Main limitations of the present review are not using individual patient data for meta-analyses and absence of correction for multiple testing.

Conclusions

There is strong evidence for PT interventions favoring intensive high repetitive task-oriented and task-specific training in all phases poststroke. Effects are mostly restricted to the actually trained functions and activities. Suggestions for prioritizing PT stroke research are given.

 

Homeopathy and stroke

A biased writeup in favor of homeopathy here;
It has the standard excuse that traditional scientific methods can't  be used because they don't honor the principles of homeopathy. What a load of crock. They have to disparage the scientific method because that method proves that homeopathy is nothing more than placebo. So if you are going down this route ask for scientific research, not this type of misleading puff piece.

Homeopathy research review

Some Homeopathy writeups for stroke here to balance this out; I will never do this.

 Alternative and Complementary Medicine for Stroke  This one is bad because it lists first aid for stroke. Yeah, lets put a bandaid on the owie in the brain.

Homeopathy and Stroke Talks about needing to correct the ' vital force'. Whoa what a load of xxx.

Cerebral Stoke and Homeopathy

Fascinating ideas from this one, a couple of lines for your amusement.

There are following remedies which are helpful in the treatment of cerebral stroke:
Aconite Nap.: good remedy for stroke, for a person who is panicky and fear of dying.
Aurum mur: when stroke is caused by depression or while person loses his face.
Opium: excellent remedy for apoplexy; comma and obstructed respiration; patient lies down; loss of consciousness with eyes half open after the brain hemorrhage. And where the hell is this person going to get opium? Never mind, after succussing numerous times there is no actual atoms of the original element in the result, so there is no need to even start out with the named element. Unless you happen to believe in magical water memory.

 

 

Quacks and Conspiracies: The undermining of science and your health

In case you use one of these; homeopathy, naturopathy, alternative medicine, you will want to at least try to read this.
http://c2cjournal.ca/wp-content/uploads/2013/01/C2CJournal_Winter2013-FINAL.pdf
In this issue of C2C Journal, we take the side of science and the scientific method over ad hominem attacks, foggy reasoning, magical thinking, and outright chicanery. Science and a proper understanding of it matters for many reasons but in the context of personal health, it matters even more.

Homeopathy is a faith-informed practice and, as such, largely impervious to rational argumentation.

In modern scientific research, the gold standard is
the hypothetico-deductive method, which operates
through the following stages:
1. Inductively gather information through
observation.
2. Formulate an explanatory theory.
3. From that theory, deduce a hypothesis (prediction).
4. Compare (test) that hypothesis against
systematic empirical evidence.
5. If the prediction is accurate, consider the theory
tentatively supported (i.e., not yet falsified)
but continue to derive other predictions for
empirical testing.
6. If the prediction is falsified, revise or abandon
the theory, and start the cycle over again.
7. Let other researchers replicate the experiment
to ensure that results are not a statistical outlier
or perhaps due to some quirk of the researcher.

Molly Crockett: Beware neuro-bunk, neuro-bollocks, neuro-flapdoodle

A great TED talk. Beware any claims that purport to help your brain.
If someone tries to sell you something with a brain on it … ask to see the evidence. Ask for the part of the story that's not being told.” (Molly Crockett)
An 11 minute video worth watching, especially if you want to  believe the neuro headlines in newspaper and magazine articles.


Brains are ubiquitous in modern marketing: Headlines proclaim cheese sandwiches help with decision-making, while a “neuro” drink claims to reduce stress. There’s just one problem, says neuroscientist Molly Crockett: The benefits of these "neuro-enhancements" are not proven scientifically. In this to-the-point talk, Crockett explains the limits of interpreting neuroscientific data, and why we should all be aware of them.
http://www.ted.com/talks/molly_crockett_beware_neuro_bunk.html

Why strokes among younger adults have soared

I dislike the picture attached to this article - Stroke Victim written over the picture. That term should never be used. It is part of the nocebo effect and never will help the survivor come to terms with their event and recover.
http://www.emaxhealth.com/11306/why-strokes-among-younger-adults-has-soared

 
Strokes are generally considered to be a condition that occurs among the elderly; however, the rate of strokes has increased significantly in the United States among younger adults. Researchers affiliated with the University of Cincinnati conducted a study to determine the reasons behind this increase. They published their findings online on November 15 in the journal Stroke.
According to the Centers for Disease Control and Prevention (CDC), nearly 800,000 individuals in the United States suffer a stroke every year, and the condition is the most common cause of serious long-term disability. A study conducted in 2007 reported that that almost 5% of people who had suffered a stroke that year were between ages 18 and 44. The investigators noted that substance abuse is a prevalent risk factor for stroke in young adults; therefore, they conducted a study to identify trends in substance abuse detection among stroke patients.
The researchers attempted to identify all patients aged 18 to 54 years experiencing a stroke (ischemic or hemorrhagic) in the Greater Cincinnati and Northern Kentucky Study region during 1993 to 1994, 1999, and 2005. (An ischemic stroke is caused by a blocked vessel while a hemorrhagic stroke is caused by leakage of blood from a blood vessel into the brain.) Demographic and clinical characteristics and substance use data were obtained retrospectively from chart review and adjudicated by physicians. The researchers reviewed medical charts for blood or urine test results of other records of substance abuse for nearly 1,200 stroke patients.
The researchers found that the number of young patients identified with a stroke increased from 1993 to 1994 (297 cases) to 2005 (501 cases). Blacks (61% vs. 51%) and men (61% vs. 47%) reported substance abuse (i.e., current smoking, alcohol abuse, or illegal drug use) more frequently than did whites and women. Overall, the use of substances increased across study periods: 45% in 1993 vs. 62% in 2005). The trend was significant for illegal drug use (3.8% in 1993 vs. 19.8% in 2005) and ever smoking (49% in 1993 vs. 66% in 2005). Documentation of both cocaine and marijuana use increased over time. In 2005, half of young adults with a stroke were current smokers, and 1 in 5 abused illegal drugs.
The authors concluded that substance abuse is common in young adults experiencing a stroke. The observed increase in substance abuse is contributing to the increased incidence of stroke in young adults. They recommended that patients aged younger than 55 years who experience a stroke should be routinely screened and counseled regarding substance abuse.
Take home message:
The results of this study are not surprising, given the deleterious effects of smoking and substance abuse. Smoking is a definite risk factor for cardiovascular disease (heart attacks and strokes). Among illegal substances, cocaine, methamphetamine, and other central nervous stimulants pose the greatest risk of a stroke. These substances significantly increase blood pressure. The increased blood pressure can cause a rupture of a blood vessel in the brain, which produces a hemorrhagic stroke.

But did the data show a higher incidence of hemorrhagic stroke than the general population? Or are you suggesting that stiffer arteries were caused by substance abuse, leading to thrown clots? I can't tell if your conclusion is supported by the evidence.